Tue.Jun 24, 2025

article thumbnail

Pharmacist Outreach Can Help Reduce Hypoglycemia Risk | ADA 2025

Drug Topics

Data presented at ADA 2025 showed patients who received outreach from a clinical pharmacist were more likely to be prescribed safer diabetes regimens.

442
442
article thumbnail

What to know about vaccine ingredients: Aluminum and thimerosal

PhRMA

It’s natural for people to have questions about vaccines and how each ingredient plays a role. Each ingredient included in a vaccine plays a necessary role in ensuring a vaccine’s safety, quality or effectiveness. All ingredients in vaccines are evaluated during the FDA vaccine review process and must meet rigorous safety standards.

Vaccines 208
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Pharmacists Play Key Role in Navigating Vaccine Misinformation and Disinformation

Drug Topics

Kevin Cleveland, PharmD, discusses how pharmacists are uniquely positioned to provide immediate, direct interactions with patients, making them vital in addressing vaccine misinformation.

Vaccines 359
article thumbnail

Childhood vaccination coverage was falling across the globe even before Covid

STAT

Childhood vaccination coverage has made leaps since 1980. But progress has significantly slowed in the last two decades. That is according to a study published in The Lancet Tuesday, which found stagnation and wide variation in childhood vaccination rates since 2010. The study, which estimated childhood vaccination coverage between 1980 and 2023 in 204 countries and territories, found that the Covid-19 pandemic significantly intensified existing immunization challenges.

Vaccines 142
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

$0 Copay Program Effectively Improved Glycemic Control | ADA 2025

Drug Topics

Researchers explored the impact of a $0 copay program on hemoglobin A1c levels in patients with type 2 diabetes who were also insured by Blue Cross and Blue Shield of Louisiana.

Insurance 341
article thumbnail

How a Big Pharma veteran looks to stand out in biotech as a unique ‘drug hunter’

PharmaVoice

J&J’s former head of R&D, now CEO of Parabilis Medicines, aims to remain above the biotech fray by taking on unique targets from which others have steered clear.

130
130

More Trending

article thumbnail

STAT+: Insurance coverage of vaccines at risk in RFK Jr.’s reshuffling of CDC’s vaccine advisers

STAT

The decision by Health and Human Services Secretary Robert F. Kennedy Jr. to remove and replace all members of the government’s independent vaccine advisory committee doesn’t just change how the nation will approach vaccine policy. It could also take money out of Americans’ wallets. Right now, anyone with health insurance — adults and children alike — who wants a vaccine that is recommended by the Advisory Committee on Immunization Practices can get it for free

article thumbnail

Q&A: PBM Unbundling, New Pricing Models Create More Transparency

Drug Topics

Morgan Lee, PhD, MPH, CPH, and Scott Halperin, PharmD, from the Pharmaceutical Strategies Group, discuss how the role of PBMs in plan design is evolving.

247
247
article thumbnail

Journavx From Vertex Pharmaceuticals Inc

Pharmacy Times

Suzetrigine, a new nonopioid pain reliever, gains FDA approval for treating moderate to severe acute pain in adults, offering a safer alternative to opioids.

FDA 114
article thumbnail

Flexible Dosing Medications to Help Your Pharmacy Thrive

Drug Topics

At the Total Pharmacy Solutions Summit Summer 2025 event, Stephanie Zimmerman, Tom Napolitano, and Luke Gunderson discussed the benefits of Real Value RX.

247
247
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Psilocybin, Ketamine, and MDMA in Cancer Care: Next Steps in Psychedelic Research

Pharmacy Times

Manish Agrawal, MD, explores the evolving role of pharmacists in psychedelic-assisted therapy, highlighting ongoing efforts to develop standardized protocols and the emerging involvement of pharmacy teams in patient education and safety.

100
100
article thumbnail

Younger Adults Disproportionately Not Treated for Cardiometabolic Risk Factors | ADA 2025

Drug Topics

When compared with adults 45 years and older, those 18 to 44 years are less likely to receive treatment or achieve target goals for cardiometabolic risk factors.

247
247
article thumbnail

Sarclisa recommended for EU approval in newly diagnosed multiple myeloma

Pharmafile

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended Sanofi’s Sarclisa (isatuximab) for approval in combination with bortezomib, lenalidomide and dexamethasone (VRd) for induction treatment in adults with newly diagnosed multiple myeloma (NDMM) eligible for stem cell transplant. If approved, this would mark Sarclisa’s fourth indication in the EU and […] The post Sarclisa recommended for EU approval in newly diagnosed multiple myeloma a

102
102
article thumbnail

STAT+: Abridge raises $300 million, pushing health AI deal-making to new heights

STAT

In one of the most substantial health tech deals of the year so far, Abridge on Tuesday announced it raised $300 million in a Series E funding round led by Andreessen Horowitz as the company hopes to capitalize on its momentum selling software that automates clinical note-writing for doctors. Abridge’s raise follows a $250 million raise announced in February and pushes the company’s valuation over $5 billion.

article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

ADA 2025: Combination of Bimagrumab and Semaglutide Shows Enhanced Fat Loss and Muscle Preservation

Pharmacy Times

New research reveals that combining bimagrumab and semaglutide enhances fat loss while preserving muscle mass, revolutionizing obesity treatment strategies.

132
132
article thumbnail

STAT+: Vaccine developer raises $45M for influenza drug trial

STAT

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Morning! Today, we talk about the readout of Compass Pathways’ psilocybin trial for major depressive disorder, see more vaccine concern and turnover at the FDA, and report from the American Diabetes Association.

article thumbnail

Nuvalent chases after Nuvation in ROS1 lung cancer

pharmaphorum

New trial data sets up a filing for Nuvalent's new-generation ROS1 inhibitor in NSCLC, although it has an uphill battle to catch rival Nuvation.

88
article thumbnail

23-Valent Pneumococcal Polysaccharide Vaccine Provides Protection Up To 6 Years Following Vaccination

Pharmacy Times

Six years following vaccination with 23-valent pneumococcal polysaccharide vaccine in a Chinese population, antibody levels remained high, though not as high as 28 days following vaccination.

article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Biogen scores Cannes Festival win with dark humored campaign

PharmaVoice

The company’s unique campaign for a rare, terminal illness nabbed millions of views and a spot on the main stage at the Cannes Lions Festival of Creativity.

130
130
article thumbnail

STAT+: Device that uses biodegradable polymers to repair peripheral nerves gets FDA clearance

STAT

A sutureless device for peripheral nerve repair could be available on the market in the coming months. The Food and Drug Administration has authorized a polymer-based device developed by medical technology company Tissium. The authorization, announced Tuesday, will give physicians a new method for treating peripheral nerve injuries. “This approval is really a game-changer for patients with peripheral nerve injuries,” said Jeffrey Karp, a Tissium co-founder who developed the device&

FDA 79
article thumbnail

Fierce Pharma - Untitled Article

Fierce Pharma

Amarin has forged a licensing deal with Italian pharma Recordati to commercialize its fish oil-derived heart pill Vascepa. Recordati will pay Amarin $25 million upfront to market the product to 59 European countries.

77
article thumbnail

STAT+: Regeneron seeks to revamp the controversial relationships between pharma and patient charities

STAT

In a bid to rework the controversial relationship between drugmakers and patient charities, Regeneron Pharmaceuticals has announced a new program in which it will match up to $200 million in donations this year to a leading foundation called Good Days. The move comes after Regeneron several months ago slashed its funding to the charity, an unexpected step that appeared largely designed to blunt the use of eye medicines sold by rivals, but one that has reduced patient access and, in turn, sparked

72
article thumbnail

5 Tips and Tricks Every PioneerRx User Needs to Know

PioneerRx

If there’s one thing we prioritize at PioneerRx, it’s innovation—and for users, that translates to new updates, new features, and new ways to use your software.

70
article thumbnail

STAT+: Top FDA drug regulator tells staff much is still in flux, as she prepares to retire

STAT

WASHINGTON — Outgoing Food and Drug Administration regulator Jacqueline Corrigan-Curay acknowledged to staff that much is still in flux at the agency, weeks before she retires. “We are leaner and therefore we have to find ways to be efficient and do things in new ways,” she told staff, according to a recording of a town hall meeting obtained by STAT.

FDA 75
article thumbnail

FDA approves AstraZeneca and Daiichi Sankyo’s Datroway for NSCLC

Pharmaceutical Technology

The FDA has approved AstraZeneca and Daiichi Sankyo's Datroway (Datopotamab deruxtecan) for adults with NSCLC.

FDA 75
article thumbnail

Cholesterol-Lowering Drugs May Significantly Increase Risk of Diabetic Microvascular Complications

Pharmacy Times

HMGCR inhibitors were found to significantly increase the risk of experiencing microvascular complications in patients with diabetes, while NPC1L1 inhibitors were found to reduce the risk.

65
article thumbnail

Pharmaceutical Technology Excellence Awards 2025: i3 Membrane

Pharmaceutical Technology

Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh

article thumbnail

AZ, Daiichi get Datroway nod in lung cancer on second try

pharmaphorum

AZ and Daiichi Sankyo have claimed FDA approval for Datroway in lung cancer after switching indications for the TROP2-directed drug.

FDA 66
article thumbnail

Timing of Antihypertensive Medication Yields No Benefit in Older Adults With Frailty

Pharmacy Times

New research reveals that bedtime antihypertensive dosing does not improve cardiovascular outcomes in frail older adults, emphasizing safety over timing.

65
article thumbnail

Life sciences a “priority sector” in UK Industrial Strategy

European Pharmaceutical Review

The UK Government has published its new 10-year Industrial Strategy , which aims to boost domestic talent and economic growth. Additional plans are due to be published, geared to key growth sectors, including life sciences. For the UK’s sector, “a successful [Industrial] strategy means ensuring the UK is not only a cutting-edge place to research and develop the medicine of the future, but also a country which seeks to embrace and use the life-changing innovations we are developing. “This w

52
article thumbnail

Novo Nordisk's fling with Hims & Hers ends in a bust-up

pharmaphorum

The alliance between Novo Nordisk and telehealth firm Hims & Hers for the distribution of GLP-1 agonist weight-loss therapies has ended in acrimony.

84
article thumbnail

Navamedic signs agreement to acquire dne pharma

Pharmaceutical Technology

Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh

article thumbnail

Best eye drops for stye

The Checkup by Singlecare

We use our eyes constantly, so when you have an eye health issue, it’s hard to ignore—especially if it’s an inflamed, itchy bump on the eyelid. These are called styes. They often stem from infected oil glands on the eyelid’s edge, and they can be pretty uncomfortable. Fortunately, there are plenty of eye care treatments to help relieve styes, including over-the-counter (OTC) and prescription eye drops or ointments.

52